The webinar will review the Italfarmaco Givinostat development program for Duchenne and Becker Muscular Dystrophy. Content that will be covered, includes:
Updates from the EPIDYS Study, a phase 3 clinical trial of Givinostat in ambulatory boys with DMD. Data from Italfarmaco’s long term studies of Givinostat in DMD populations. 30 minute Q & A.
Speakers: Paolo Bettica, MD, PhD Vice President of Research and Development, Italfarmaco S.p.A Michael Kelly, Chief Scientific Advisor, CureDuchenne Ana Christensen, Patient Science Liaison, TRINDS
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree